Dear Sir, Please find attached audited financial results for the year ended March 31, 2026.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 10.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health Ltd reported audited financial results for FY26 ended March 31, 2026. Revenue from operations grew to ₹1,40,797 lakhs compared to ₹93,417 lakhs in the prior 9-month period (July 2024 – March 2025). Net Profit after tax stood at ₹32,691 lakhs versus ₹23,441 lakhs in the comparable prior period. The company declared a final dividend of ₹45 per equity share, bringing total dividend for the year to ₹205 per share (including interim and special dividends). The statutory auditors Haribhakti & Co. LLP issued an unmodified opinion on the financial statements. Note: The company changed its financial year-end from June 30 to March 31, making the previous period only 9 months versus the current 12-month period, affecting comparability. On a sequential Q4 basis, revenue grew ~19% YoY and PAT grew ~55% YoY.
Strong full-year results with revenue and profit growth; clean audit with unmodified opinion; heavy dividend payout of ₹205 per share signals confidence but reduces retained earnings. The stock appears to be in a growth phase with improving bottom line.